A carregar...
Cost-utility analysis of de-escalating biological disease-modifying anti-rheumatic drugs in patients with rheumatoid arthritis
OBJECTIVE: Recent guideline updates have suggested de-escalating DMARDs when patients with rheumatoid arthritis achieve remission or low disease activity. We aim to evaluate whether it is cost-effective to de-escalate the biological form of DMARDs (bDMARDs). METHODS: Using a Markov model, we perform...
Na minha lista:
| Publicado no: | PLoS One |
|---|---|
| Main Authors: | , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
Public Library of Science
2020
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6939943/ https://ncbi.nlm.nih.gov/pubmed/31895926 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1371/journal.pone.0226754 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|